A Study to Evaluate Ketamine for the Treatment of Rett Syndrome
Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This 2 cohort, sequential, ascending dose study will assess the safety, tolerability and
efficacy of oral ketamine dosed in a single 5-day BID regimen in addition to placebo, in a
4-week cross-over design in patients with Rett Syndrome. Approximately 12 patients per cohort
are anticipated to participate for approximately 8-10 weeks at approximately 7 US study
centers.
Phase:
Phase 2
Details
Lead Sponsor:
Rett Syndrome Research Trust
Collaborators:
Vanderbilt University Vanderbilt University Medical Center